Marker Therapeutics

Historical price data

Marker Therapeutics is advancing a differentiated cell therapy platform that harnesses the natural T-cell repertoire without genetic modification. The company's lead candidate, MT-601, targets six tumor-associated antigens and is in Phase 1 for lymphoma patients who have failed or are ineligible for CAR-T therapy. Its strategy focuses on addressing the significant unmet need in solid tumors and relapsed hematologic malignancies with a potentially safer, more durable therapeutic approach, leveraging foundational research from Baylor College of Medicine.

Multi-Antigen Recognizing (MAR) T cell platform: a non-genetically modified, autologous T-cell therapy expanded ex vivo to target multiple tumor-associated antigens simultaneously, leveraging the body's natural T-cell receptor repertoire.

Competes against approved CAR-T therapies on potential safety and multi-targeting advantages, and against next-gen cell therapies (allogeneic, TCR-T) and bispecific antibodies. Differentiation lies in its non-genetically modified, multi-antigen natural T-cell approach.